SBMFF (Sino Biopharmaceutical) EBIT: $1,009 Mil (TTM As of Dec. 2025)


SBMFF Sino Biopharmaceutical Ltd SBMFF
62 GF Score
Price $0.60
GF Value $0.68
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Sino Biopharmaceutical EBIT?

Sino Biopharmaceutical SBMFF -4.96% 62 EBIT is $1,009 Mil as of Dec. 2025. GuruFocus rates SBMFF with a GF Score™ of 62/100 and a GF Value™ of $0.68 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Sino Biopharmaceutical's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2025 was $161 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was $1,009 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Sino Biopharmaceutical's annualized ROC % for the quarter that ended in Dec. 2025 was 4.26%. Sino Biopharmaceutical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 22.52%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Sino Biopharmaceutical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was 9.49%.


Sino Biopharmaceutical  (OTCPK:SBMFF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Sino Biopharmaceutical's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=980.468 * ( 1 - 66.32% )/( (6957.148 + 8562.614)/ 2 )
=330.2216224/7759.881
=4.26 %

where

Invested Capital(Q: Jun. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=10430.395 - 2224.054 - ( 2760.655 - max(0, 3460.895 - 4710.088+2760.655))
=6957.148

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=10791.944 - 913.805 - ( 3260.09 - max(0, 3577.858 - 4893.383+3260.09))
=8562.614

Note: The Operating Income data used here is two times the semi-annual (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Sino Biopharmaceutical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=321.316/( ( (1400.175 + max(-796.546, 0)) + (1452.948 + max(-1057.135, 0)) )/ 2 )
=321.316/( ( 1400.175 + 1452.948 )/ 2 )
=321.316/1426.5615
=22.52 %

where Working Capital is:

Working Capital(Q: Jun. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(1135.602 + 293.001 + 0.096999999999753) - (2224.054 + 0 + 1.192)
=-796.546

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(809.415 + 320.403 + 195.607) - (913.805 + 0 + 1468.755)
=-1057.135

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Sino Biopharmaceutical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=1008.823/10626.068
=9.49 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sino Biopharmaceutical EBIT Related Terms


Sino Biopharmaceutical EBIT Historical Data

* Premium members only.

The historical data trend for Sino Biopharmaceutical's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sino Biopharmaceutical EBIT Chart

Sino Biopharmaceutical Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2,964.42 809.61 827.03 765.39 1,025.35

Sino Biopharmaceutical Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 358.20 519.35 247.89 848.17 160.66

SBMFF vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Sino Biopharmaceutical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sino Biopharmaceutical EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Sino Biopharmaceutical's EV-to-EBIT falls into.


SBMFF
62GF Score
Sino Biopharmaceutical Ltd SBMFF
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Sino Biopharmaceutical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $1,009 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $1,009 Mil mean?
Sino Biopharmaceutical (SBMFF) has a EBIT of $1,009 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sino Biopharmaceutical.
Is Sino Biopharmaceutical's EBIT too high?
Sino Biopharmaceutical's current EBIT is $1,009 Mil. Overall, Sino Biopharmaceutical has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sino Biopharmaceutical's EBIT compare to VRTX and REGN?
Sino Biopharmaceutical's EBIT of $1,009 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Sino Biopharmaceutical. Sino Biopharmaceutical's current EBIT is $1,009 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sino Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Sino Biopharmaceutical (SBMFF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.68, compared to a current price of $0.60 — trading 11.5% below its estimated fair value. The current EBIT is $1,009 Mil. Sino Biopharmaceutical's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Sino Biopharmaceutical (SBMFF), the current EBIT is $1,009 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sino Biopharmaceutical (SBMFF) Overvalued in 2026?

Based on GuruFocus' analysis, Sino Biopharmaceutical stock appears to be undervalued. The current stock price of $0.60 is trading 11.5% below its estimated GF Value™ of $0.68. GuruFocus considers Sino Biopharmaceutical to be Modestly Undervalued.

Key valuation signals for SBMFF:

  • EBIT: $1,009 Mil
  • GF Value™: $0.68 vs. price of $0.60 (11.5% below fair value)
  • GF Score™: 62/100 with 4 warning signs

No single metric tells the full story. See the SBMFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Sino Biopharmaceutical Business Description

Address 1 Harbour Road, Unit 09, 41st Floor, Office Tower, Room 4109, Convention Plaza, Wanchai, Hong Kong, HKG
Sino Biopharmaceutical Ltd is an investment holding company. The company and its subsidiaries are principally engaged in the research and development, production and sale of a series of pharmaceutical products. Its business covering the entire industrial chain of R&D, production and commercialization of drugs, biological products and high-end generic drugs. The company's therapeutic areas include: oncology, liver disease, respiratory, and surgery/pain relief. The company's revenue was generated from the sale of pharmaceutical products in the Chinese mainland.
62GF Score

Get the complete analysis for SBMFF

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.60
Price
$0.68
GF Value